Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-β Disaggregation

Peter K. Windsor 1, Stephen P. Plassmeyer 1, Dominic S. Mattock 1, Jonathan C. Bradfield 1, Erika Y. Choi 2, Bill R. Miller III 1, * and Byung Hee Han 2, *

1 Department of Chemistry, Truman State University, Kirksville, MO 63501, USA; pkw4146@truman.edu (P.K.W.); stephenplassmeyer@gmail.com (S.P.P.); dsm7762@truman.edu (D.S.M.); jcb6582@truman.edu (J.C.B.)
2 Department of Pharmacology, A.T. Still University, Kirksville, MO 63501, USA; erikachoi92@gmail.com

Abstract: Deposition of amyloid β (Aβ) fibrils in the brain is a key pathologic hallmark of Alzheimer’s disease. A class of polyphenolic biflavonoids is known to have anti-amyloidogenic effects by inhibiting aggregation of Aβ and promoting disaggregation of Aβ fibrils. In the present study, we further sought to investigate the structural basis of the Aβ disaggregating activity of biflavonoids and their interactions at the atomic level. A thioflavin T (ThT) fluorescence assay revealed that amentoflavone-type biflavonoids promote disaggregation of Aβ fibrils with varying potency due to specific structural differences. The computational analysis herein provides the first atomistic details for the mechanism of Aβ disaggregation by biflavonoids. Molecular docking analysis showed that biflavonoids preferentially bind to the aromatic-rich, partially ordered N-termini of Aβ fibril via the π–π interactions. Moreover, docking scores correlate well with the ThT EC50 values. Molecular dynamic simulations revealed that biflavonoids decrease the content of β-sheet in Aβ fibril in a structure-dependent manner. Hydrogen bond analysis further supported that the substitution of hydroxyl groups capable of hydrogen bond formation at two positions on the biflavonoid scaffold leads to significantly disaggregation of Aβ fibrils. Taken together, our data indicate that biflavonoids promote disaggregation of Aβ fibrils due to their ability to disrupt the fibril structure, suggesting biflavonoids as a lead class of compounds to develop a therapeutic agent for Alzheimer’s disease.

Keywords: neurodegenerative disease; Alzheimer’s disease; amyloid aggregation; anti-amyloid compounds; drug discovery; naturally occurring flavonoids; polyphenols; amentoflavone

1. Introduction

Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with incidence rates expected to rise steadily in the coming decades [1]. Presently available pharmacological treatments help to manage symptoms by compensating for dysregulation of cholinergic and glutamatergic signaling but with minimal effect to either slow or halt the disease process [2]. Towards defining a fundamental molecular etiology of AD as a target for drug development, the amyloid cascade hypothesis has been a leading model for linking the deposition of amyloid β (Aβ) peptide with the onset of neurodegeneration and cognitive decline [3]. Generated from the aberrant cleavage of amyloid precursor protein (APP), Aβ peptide accumulates through a process of misfolding and aggregation in which natively α-helical monomers associate to form an ensemble of oligomeric intermediates. These intermediates in turn promote the formation of insoluble β-rich fibrils [4]. Although a precise mechanism for aggregation remains uncertain, fibrils display self-templating growth and serve as nucleation sites for further accelerated aggregation [5]. Diffusible oligomeric species, either generated as intermediates of this aggregation pathway or derived from fragmentation of extant fibrils [6], have been shown to induce neurotoxic
stress by disrupting cell membrane integrity, signal transduction, and other key homeostatic mechanisms [7].

Given the centrality of \( \text{A}\beta \) aggregates to the disease process, perturbation of the aggregation pathway has become a popular target for developing novel pharmacological interventions [8]. Previous studies have focused on the discovery and design of small molecules [9], peptides [10], peptidomimetics [11] which help prevent aggregates from forming or increase their solubility and clearance from the brain. Numerous natural products have been investigated in AD models for their neuroprotective effects, which are mediated in part by direct interactions with \( \text{A}\beta \) fibrils and oligomers [12]. Flavonoids are one such class of naturally occurring polyphenols with well characterized neuroprotective effects in the presence of \( \text{A}\beta \) and other stressors [13]. Structurally diverse, these compounds are generally categorized as mono- or biflavonoids depending on the presence of either one or two functional flavone units. Similar to other polyphenolic aggregation inhibitors [14], there is evidence that flavonoids promote the accumulation of less toxic, off-target oligomers and thereby reduce amyloid load [15]. However, compared to monoflavonoids, bioflavonoids more potently and specifically reduce amyloid-associated toxicity [16].

The precise mechanism of small molecular aggregation inhibitors remains poorly understood [17], largely due to the structural heterogeneity and complex aggregation dynamics of \( \text{A}\beta \). Monomeric and oligomeric intermediates are metastable under physiological conditions, and the aggregates formed display a high degree of polymorphism. Furthermore, several isoforms of \( \text{A}\beta \) naturally occur, with \( \text{A}\beta_{40} \) and \( \text{A}\beta_{42} \) being the most abundant, and each isoform has distinct aggregation kinetics and structural features [18]. Salt-bridge formation between the side chain of K28 and the carboxylate of the additional C-terminal A42 in \( \text{A}\beta_{42} \) modifies the misfolding pathway relative to \( \text{A}\beta_{40} \) [19], contributing to faster aggregation rates and aggregates with greater neurotoxicity [20]. Methods for selecting monomorphic fibrils by seeding and careful selection of conditions have allowed for reproducible control over the fibril species generated in vitro, allowing for structural determination via electron microscopy [21] as well as both solution and solid-state NMR-based structural modeling [22]. Structural information of inhibitor interactions with monomers in solution has been inferred through NMR experiments [23]; however, such structural information regarding oligomers and fibrils remains experimentally inaccessible [24].

Given the limitations of experimental methods, computational modelling has emerged as a valuable tool for studying \( \text{A}\beta \)-inhibitor interactions in atomistic detail [25]. Through the use of molecular docking and molecular dynamics (MD) simulations, detailed models have been developed to describe how small molecule inhibitors bind to key structural motifs of numerous \( \text{A}\beta \) polymorphs [26]. With advantages in speed and throughput, molecular docking provides a powerful tool for screening leads and interrogating potential binding sites on \( \text{A}\beta \) [27]. Docked poses can be further refined using unrestrained MD simulations which also reveal key conformational changes and mechanistic details underlying recognition and binding specificity. Ultimately, this modeling strategy can illustrate how inhibitor-induced structural changes lead to fibril destabilization and disassembly.

There are growing lines of evidence that biflavonoids such as amentoflavone afford the neuroprotective effects on many in vitro as well as in vivo settings of neurological diseases, including strokes [28,29], Alzheimer’s disease [30–33], and Parkinson’s disease [34]. Recently, we and others have reported that biflavonoids not only inhibit the formation of \( \text{A}\beta_{40} \) and \( \text{A}\beta_{42} \) fibrils but also disaggregate preformed-\( \text{A}\beta \) fibrils with varying efficacy [35,36]. For example, we found that amentoflavone most potently inhibits fibrillization of \( \text{A}\beta_{42} \) and disaggregates \( \text{A}\beta_{42} \) fibrils in a cell-free assay system utilizing thioflavin T (ThT). A structure-activity relationship exhibited that the substitution of hydroxyl groups with apolar functional groups attenuates the effects of biflavonoids on \( \text{A}\beta_{42} \) disaggregation, suggesting the importance of hydrogen bond donors at key positions. However, the structural basis of anti-amyloidogenic activity of biflavonoids and the interactions between \( \text{A}\beta_{42} \) and biflavonoids at the atomic levels remained to be investigated.
In the present study, we chose five amentoflavone-type biflavonoids to examine the structure–activity relationship for the Aβ_{42} disaggregating activity by the ThT fluorescence assay method. Although biflavonoids have been studied previously, we utilized computational methods to provide the first extensive structural description of how these biflavonoids promote disaggregation of Aβ_{42} fibrils. To further determine how minor structural variations in each position of hydroxyl groups contribute to observed differences in inhibitor activity on an atomic level, molecular modeling and molecular dynamic simulations were employed. We used an all-atom structure for a disease-relevant polymorph of Aβ_{42} fibril [37] to model the site-specific binding and disaggregation mechanisms of several biflavonoids (Figure 1). The model structure exhibits peptides with an S-shaped fold forming dimeric layers with C_2 symmetry and has been characterized in independent studies of Aβ_{42} fibrils [27,37]. The structure includes all 42 residues, including the partially ordered N-terminal residues, allowing for a complete evaluation of potential binding sites. Using the entire fibril surface as a search space, molecular docking simulations were performed to identify optimal binding poses for five biflavonoids. Conformational perturbations to the fibril in complex with these poses were further examined through explicit-solvent unrestrained MD simulations on the microsecond timescale. Analysis of these trajectories highlights specific binding interactions near the N-terminus of the Aβ peptides in the fibril model, and large-scale structural changes occurring on the nanosecond timescale suggest a mechanism for biflavonoid-driven structural remodeling.

**Figure 1.** Disease-relevant polymorph of Aβ_{42} fibril (PDB: 2NAO) used for molecular docking and molecular dynamic (MD) simulations. β-structured regions are shown in cyan and non-β-structured regions are shown in yellow.

### 2. Results and Discussion

#### 2.1. Thioflavin T Fluorescence Assay

The highly aromatic biflavonoid structure can be seen in Figure 2. The R-groups represent either a methyl group or a hydrogen atom, resulting in a methoxy substituent or hydroxyl substituent, respectively. In order to determine the role of hydrogen bonding functional groups, a series of biflavonoids was chosen with methoxy groups substituted at key positions on the amentoflavone (AMF) scaffold. The different R-groups for the biflavonoids used in this study can be found along with corresponding experimentally derived EC_{50} values determined from the Thioflavin T fluorescence assays (Figure 2). The assay results reveal that AMF exhibits the most potent effect on promoting disaggregation of Aβ_{42} fibrils while STF is the least effective. Sirimangkalakitti et al. recently published results testing the inhibitory effects of these biflavonoids with Aβ_{40} and also found that STF had a lower inhibitory effect relative to other the mono-methoxy bioflavonoids [35]. They present that AMF, SQF, BIL, and PCF all had similar inhibitory effects, whereas we found that these biflavonoids differed in their effects. We believe these discrepancies are due to the structural differences between Aβ_{40} and Aβ_{42}. 
They present that AMF, SQF, BIL, and PCF all had similar inhibitory effects, whereas we found that these biflavonoids differed in their effects. We believe these discrepancies are due to the structural differences between A

AMF directly disrupted fibrillar structure of Aβ fibrils to amorphous aggregates as determined by atomic force microscopy [38]. The experimental results from the thioflavin T fluorescence assays demonstrate that biflavonoid compounds exhibit different activities on Aβ fibril disaggregation. Methoxy groups at positions R₁ and R₄ have lower penalties on potency relative to methoxy groups at R₂ and R₃ which exhibit larger penalties on potency. Nevertheless, these results do not suggest atomistic details as to how these biflavonoids destabilize the Aβ fibril. Therefore, molecular docking and molecular dynamics (MD) were employed to elucidate how the biflavonoids affect Aβ fibril stability.

2.2. Molecular Docking of Biflavonoids

Molecular docking was carried out using the AutoDock Vina scoring function via the PyRx interface. An exhaustive docking method was used to generate sufficient sampling to be compared to EC₅₀ values. The docking results for the most negative binding cluster for each biflavonoid can be found in Figure 3A. Furthermore, there is a significant positive correlation between the experimental EC₅₀ values from the ThT fluorescence assays and the docking scores for the biflavonoids (Figure 3B).

Additionally, the most negative binding cluster for each biflavonoid was located near the partially ordered N-terminal residues 6–14 of the Aβ fibril (Figure 4). The preferential binding of each molecule to the N-terminal pocket was likely due to the presence of aromatic residues (H₆, Y₁₀, H₁₃), and the ability of the molecule to fill the space in the pocket. The highly aromatic biflavonoid formed π–π interactions with the aromatic-rich N-terminal pocket of the fibril to stabilize the biflavonoid-fibril complex. A previous computational study has suggested that small aromatic molecules like biflavonoids primarily interact with C-terminal residues and secondarily interact with N-terminal residues [39]. Discrepancies in the observed primary binding site are most likely due to differences in
the Aβ polymorph used in each study. Wang et al. used a pentameric Aβ fibril that was modeled after an incomplete NMR-derived Aβ fibril. The resulting fibril did not contain the N-terminal pocket that is present in the disease-relevant polymorph used in the current study. Recently, a study by Sun et al. [36] also completed docking experiments which confirmed that AMF preferentially interacts with the N-terminal of the Aβ fibril. While Sun et al. observed similar interactions between the Aβ fibril and amentoflavone, the study presented here used a disease-relevant polymorph of the Aβ fibril (PDB: 2NAO) as opposed to other Aβ40 and Aβ42 structures. Here, a rigorous docking method was used to confirm biflavonoid binding modes and docking scores. Furthermore, the present study docked multiple biflavonoids, confirming that the proposed binding pocket is consistent with biflavonoid variation.

| Compound | Avg. Weighted Docking Score (kcal·mol⁻¹) |
|----------|-----------------------------------------|
| AMF      | -7.91 ± 0.01                            |
| SQF      | -7.78 ± 0.01                            |
| BIL      | -7.78 ± 0.01                            |
| STF      | -7.70 ± 0.01                            |
| PCF      | -7.91 ± 0.01                            |

Figure 3. Results from docking biflavonoids to Aβ42 (PDB: 2NAO). (A) Average weighted docking scores ± S.E.M. for the most negative binding cluster for each biflavonoid calculated from the AutoDock Vina scoring function via the PyRx interface. Simulations were performed with Aβ42 in the presence of amentoflavone (AMF), sequoiaflavone (SQF), bilobetin (BIL), sotetsuflavone (STF), and podocarpusflavone (PCF). (B) Experimental EC50 values plotted against the average weighted AutoDock Vina docking scores for each biflavonoid cluster bound to the Aβ fibril showing a positive correlation (R²: 0.866, p = 0.022).

Figure 4. Depiction of the top docking poses from PyRx. (A) Aβ42 fibril structure (PDB: 2NAO) used for molecular docking and molecular dynamics (MD). (B) The most negative binding conformation from the docking calculations for the five biflavonoids overlaid in the N-terminal pocket of the Aβ42 fibril.

2.3. Molecular Dynamics

In addition to molecular docking, explicit-solvent unrestrained MD was performed to study the dynamic interactions between the Aβ fibril and biflavonoid molecules. The Aβ fibril complexed to the most negative binding mode for each biflavonoid from our initial docking screen was used as the starting structure for each simulation. Additionally, a biflavonoid-free simulation was performed to evaluate the behavior of the Aβ fibril in
the absence of a biflavonoid. Each system was minimized, heated, and equilibrated prior to unrestrained MD in an effort to minimize the bad contacts of the system. Each system was then allowed to propagate for 1.0 μs. Various analyses were performed to analyze the collected data, including root mean square deviation (RMSD), per-residue free energy decomposition analysis, principal component analysis (PCA), secondary structure analysis, and hydrogen bond analysis.

2.3.1. Structural Dynamics

RMSD can be used as a measure of conformational stability over the course of a simulation. Figure 5 shows the all-atom RMSD for the ligand-free and ligand-bound simulations over 1000 ns. The equilibrated structure for each simulation was used as the reference structure for these calculations. It is clear from Figure 5 that the ligand-free simulation exhibits the smallest deviation from the starting structure. In contrast, the ligand-bound simulation with PCF exhibits the largest deviation from the starting structure. All of the ligand-bound simulations exhibit a larger deviation from the starting structure relative to the ligand-free simulation, indicating that the biflavonoids cause conformational changes within the fibril, promoting disaggregation. Discrepancies between EC_{50} values and RMSD are likely a result of the smaller timescales sampled in our simulations (1.0 μs) relative to in vitro disaggregation (hours). While full disaggregation is able to be observed in vitro, our simulations only represent a small portion of this disaggregation process. Additionally, EC_{50} values were determined using full Aβ aggregates, whereas simulations were carried out using a six-peptide aggregate.

![Figure 5](image)

Figure 5. Comparative all atom RMSD for ligand-free and ligand-bound simulations using the equilibrated structure for each simulation as the reference structure. Simulations were performed with Aβ_{42} alone (Fibril) or in the presence of bilobetin (BIL), amentoflavone (AMF), sotetsuflavone (STF), sequoiaflavone (SQF), and podocarpusflavone (PCF).

2.3.2. Per-Residue Free Energy Decomposition Analysis

Solvation free energy for the biflavonoid-fibril complexes, ΔG_{decomp}, was measured and decomposed per-residue to characterize the interactions stabilizing each inhibitor within the binding pocket. The major residues contributing to complex stability were F4, H6, Y10, V12, H13, and H14 (Table 1). During the simulations, these non-polar and/or aromatic residues adjust such that they form favorable van der Waals (VDW) interactions. For these residues, comparison of the VDW, electrostatic, and solvation energy contributions to the total solvation free energy shows that the average ΔG_{vdw}, ΔG_{ele}, and ΔG_{nonpolar} values are stabilizing (negative) whereas the average ΔG_{polar} values are destabilizing (positive). Favorable π-π interactions formed with aromatic residues F4, H6, Y10, H13, and
H14 (Figure 6), as estimated by $\Delta G_{\text{vdw}}$, account for the greatest stabilizing component to $\Delta G_{\text{decomp}}$. Full $\Delta G_{\text{decomp}}$ data can be found in the Supporting Information. Combining the most stable conformations from docking and the free energy analysis from MD, we hypothesize that the favorable biflavonoid–fibril $\pi-\pi$ interactions promote initial binding of the biflavonoid to the Aβ fibril and help maintain the overall protein-ligand complex.

### Table 1. $\Delta G_{\text{decomp}}$, $\Delta G_{\text{vdw}}$, $\Delta G_{\text{ele}}$, $\Delta G_{\text{polar}}$, and $\Delta G_{\text{nonpolar}}$ of primary binding residues averaged across the five ligand-bound simulations.

| Residue | Avg. $\Delta G_{\text{decomp}}$ (kcal·mol$^{-1}$) | Avg. $\Delta G_{\text{vdw}}$ (kcal·mol$^{-1}$) | Avg. $\Delta G_{\text{ele}}$ (kcal·mol$^{-1}$) | Avg. $\Delta G_{\text{polar}}$ (kcal·mol$^{-1}$) | Avg. $\Delta G_{\text{nonpolar}}$ (kcal·mol$^{-1}$) |
|---------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| F4      | $-0.70 \pm 1.00$                | $-0.95 \pm 1.23$                | $-0.07 \pm 0.17$                | $+0.42 \pm 0.52$                | $-0.10 \pm 0.14$                |
| H6      | $-0.84 \pm 0.79$                | $-1.28 \pm 1.29$                | $-0.34 \pm 0.68$                | $+0.89 \pm 0.90$                | $-0.11 \pm 0.15$                |
| Y10     | $-1.17 \pm 1.13$                | $-1.49 \pm 1.43$                | $-0.41 \pm 0.74$                | $+0.89 \pm 0.89$                | $-0.15 \pm 0.14$                |
| V12     | $-0.42 \pm 0.65$                | $-0.56 \pm 0.34$                | $-0.34 \pm 1.24$                | $+0.32 \pm 0.71$                | $-0.04 \pm 0.05$                |
| H13     | $-0.48 \pm 0.64$                | $-0.74 \pm 0.92$                | $-0.24 \pm 0.22$                | $+0.57 \pm 0.56$                | $-0.07 \pm 0.09$                |
| H14     | $-0.32 \pm 0.41$                | $-0.58 \pm 0.63$                | $-0.22 \pm 0.40$                | $+0.54 \pm 0.60$                | $-0.06 \pm 0.07$                |

Figure 6. Amentoflavone in the N-terminal pocket of the Aβ$_{42}$ fibril being stabilized by F4, H6, Y10, V12, H13, and H14. This image is representative of the $\pi-\pi$ interactions that were observed in the other biflavonoid simulations.

#### 2.3.3. Principal Component Analysis

Principal component analysis (PCA) was used to reduce the dimensionality of the MD simulations to elicit the dominant modes of motion for the Aβ fibril–biflavonoid complex [40]. This was in an effort to elucidate the motions and conformations that characterize the disaggregation of the Aβ fibril. The trajectories of the five ligand-bound simulations and the ligand-free simulation were concatenated into a single conformational ensemble, and five dominant modes of motion were extracted using PCA [41]. The equilibrated fibril structure was used as the reference structure for each system. The trajectories were stripped of all atoms except the $\alpha$-carbons of the peptide backbone to isolate the motion of the peptides [42]. Figure 7A,B show PCA scatter plots generated for three ligand-bound simulations and the one ligand-free simulation projected on to the first and second dominant modes of motion and first and third dominant modes of motion. Data for the second and third dominant modes of motion can be found in the Supporting Information along with the PCA data for all six simulations. The scatter plot shows that the eigenvalues from the MD trajectory are varied between the four systems. This suggests that the disaggregation mechanism is unique between biflavonoids even though PCA is unable to reveal how these mechanisms are structurally different. The ligand-bound simulation trajectories show less variation in the dominant normal mode compared to the ligand-free simulation.
indicating that the ligand-bound simulations are less dynamic than the ligand-bound simulations. The ligand-bound complexes move further away from the starting conformations and stabilize after reaching the new conformation, reflected by denser clusters for PCA but increased RMSD. This can be visually observed in the MD trajectories of the ligand-bound simulations as the biflavonoids collapse the fibril structure thus limiting the degrees of motion available to the complex.

**Figure 7.** Principal component analysis (PCA) results from the ligand-free simulation and three representative ligand-bound simulations. Projection of the individual trajectories onto the first and second dominant modes of motion and (A) first and third dominant modes of motion (B) for three ligand-bound simulations and the ligand-free simulation showing the difference in motion between systems. Simulations were performed with Aβ42 alone (Fibril) or in the presence of bilobetin (BIL), amentoflavone (AMF), and sotetsuflavone (STF). Projections for the second and third dominant modes of motion can be found in the Supporting Information along with the data for all six simulations.

Using the Normal Mode Wizard plug-in of VMD, these modes of motion were visualized in the form of porcupine plots. The porcupine plots for the first, second, and third dominant modes of motion can be found in the Supporting Information, where the vectors represent the general direction of the α-carbon for each amino acid in the fibril. The N-termini and core of each set of peptides fold towards each other while the C-termini of each set also fold towards each other but in the opposite direction relative to the N-termini and core. The second and third dominant modes of motion show similar motions. The observed folding motion twists the Aβ peptides within the fibril and decreases the hydrogen bonding potential in the peptide backbone. This motion destabilizes the β-sheets within the fibril, promoting collapse of the fibril structure.

2.3.4. Secondary Structure Analysis

The rigid structure and stability of the Aβ42 fibril has been attributed to high β-sheet content throughout the fibril. The total β-sheet content of the fibril was quantified over the course of the simulation to observe whether the biflavonoids disrupted the secondary structure. Specifically, the secstruct module of cpptraj was used to assign a DSSP secondary structure label to each residue for each frame of a trajectory. The percentage of residues designated as parallel β-strand was reported as the β-sheet content.

All simulations started with the fibril at 35% β-sheet content and decreased steadily over the first 500 ns. The decrease in β-sheet content stabilized during the last 500 ns for each simulation. The change in β-sheet content over time for the ligand-bound simulations and ligand-free simulation can be seen in Figure 8A. The ligand-free simulation showed a slight decrease in content relative to the starting structure, stabilizing at 29% following equilibration and relaxation. The ligand-bound simulations showed a larger decrease in β-sheet content relative to the ligand-free simulation, stabilizing around 20%. This larger decrease in β-sheet content suggests that the presence of biflavonoids promotes new structural conformations of the Aβ42 fibril.
Hydrogen bond analysis was used to investigate hydrogen bonding interactions that were important for biflavonoid-fibril binding. Specifically, the hydrogen bonding between the biflavonoid R-groups and the fibril were investigated to determine how R-group differentiation affected interactions with the fibril. Biflavonoids with hydroxyl groups at R2 or R3 formed hydrogen bonds with the peptide backbone over a significant portion of the simulation. Hydrogen bond formation between hydroxyl groups at R2/R3 and the peptide backbone suggests a reason for β-sheet destabilization (Figure 9). The hydrogen bonding between hydroxyl R2/R3 and the peptide backbone displaces the peptide backbone to peptide backbone hydrogen bonding that is responsible for β-sheet formation. Additionally, the presence of hydroxyl groups at R2/R3 and their hydrogen bonding activity is consistent with the experimental EC50 values. When R2/R3 are both hydroxyl groups (e.g., AMF, SQF, and PCF), significant hydrogen bonding is observed with the peptide backbone, and this is consistent with the lower EC50 values. When either R2 or R3 are occupied by methoxy groups (e.g., BIL and STF), hydrogen bonding with the peptide backbone does not occur which is consistent with the higher EC50 values. This further supports that hydroxyl groups at R2/R3 are important for fibril destabilization. No consistent hydrogen bonding trends were observed between R1/R4 and the peptide backbone. R1/R4 mainly formed hydrogen bonds with amino acid side chains and solvent and do not appear to
contribute significantly to fibril destabilization. The percentage of frames with hydrogen bonds between the peptide backbone and R2/R3 for each biflavonoid can be found in Table 2.

![Image of Amentoflavone (AMF) forming hydrogen bonds between R2 and R3 and the peptide backbone with hydrogen bond formation percentages by respective R-group (amino acid R-groups are stripped for clarity).](image_url)

**Figure 9.** Amentoflavone (AMF) forming hydrogen bonds between R2 and R3 and the peptide backbone with hydrogen bond formation percentages by respective R-group (amino acid R-groups are stripped for clarity).

| Compound | R2 (%) | R3 (%) |
|----------|--------|--------|
| AMF      | 37     | 26     |
| SQF      | 26     | 24     |
| BIL      | 0      | 49     |
| STF      | 75     | 0      |
| PCF      | 11     | 39     |

**Table 2.** Percent trajectory for which R2 and R3 formed hydrogen bonds with the peptide backbone.

Hydrogen bonding analysis was also performed to investigate the backbone hydrogen bonding that stabilizes the Aβ fibrils in the absence and presence of the biflavonoid inhibitors. The original NMR structure (PDB: 2NAO) contains six peptides (Chains A–F) where Chains A–C forms one β-sheet and Chains D–F form another sheet (Figure 1). We observed a decrease in total backbone hydrogen bonding for all simulations with a biflavonoid bound to the fibril relative to the ligand-free simulation (Table S2). Throughout the ligand-free simulation, more backbone hydrogen bonds were present for longer in Chains D–F than Chains A–C (Figure 10A). The docking results demonstrate that the biflavonoid ligands preferentially bound to Chains D–F in all instances, specifically near residues 6–14 with multiple aromatic amino acids. In all ligand-bound simulations (Figure 10B–F), we observed a noticeable decrease in prevalent backbone hydrogen bonding (>50%) for Chains D–F in the regions where the biflavonoids were bound. The decrease was most significant at or near where the biflavonoids interacted most with the fibril (blue shaded region of Figure 10B–F). These results further demonstrate that the loss of β-sheet character observed during ligand-bound simulations (Figure 8) arises from the loss of backbone hydrogen bonding between the Aβ42 peptides. This suggests that the presence of the biflavonoids directly disrupts the backbone hydrogen bonds that stabilize the secondary structure of the Aβ fibril.
residues 6–14 with multiple aromatic amino acids. In all ligand-bound simulations (Figure 10B–F), we observed a noticeable decrease in prevalent backbone hydrogen bonding (>50%) for Chains D–F in the regions where the biflavonoids were bound. The decrease was most significant at or near where the biflavonoids interacted most with the fibril (blue shaded region of Figure 10B–F). These results further demonstrate that the loss of β-sheet character observed during ligand-bound simulations (Figure 8) arises from the loss of backbone hydrogen bonding between the Aβ42 peptides. This suggests that the presence of the biflavonoids directly disrupts the backbone hydrogen bonds that stabilize the secondary structure of the Aβ fibril.

Figure 10. Protein backbone hydrogen bonding analysis derived from simulations of Aβ42 with (A) no ligand, (B) amentoflavone (AMF), (C) bilobetin (BIL), (D) podocarpusflavone (PCF), (E) sequoiaflavone (SQF), and (F) sotetsuflavone (STF). Hydrogen bonds percentages were calculated over each 1.0 µs simulation, and were categorized by the percent of frames with backbone hydrogen bonds present: >50% (green), 25–50% (yellow), 10–25% (orange) and less than 10% (red). Each line depicted shows a backbone hydrogen bond present during the simulation to and from one of the six peptides (Chains A–F) from the original structure (PDB 2NAO). The blue highlighted region depicts the area with the most direct contact with each ligand from docking. Larger images of each panel with amino acids 1–42 listed explicitly can be found in the SI.

3. Materials and Methods

3.1. Thioflavin T Fluorescence Assay

To test the effects of biflavonoids on promoting disaggregation of Aβ42 fibrils, we performed the ThT fluorescent assay per the published method [38,43,44]. Briefly, monomeric Aβ42 (American Peptide Company, Sunnyvale, CA, USA) was dissolved in hexafluoroisopropanol, air dried, and dissolved in dimethyl sulfoxide (DMSO) and kept at −20 °C until use. Aβ42 was then diluted in PBS buffer (50 mM NaH2PO4 and 100 mM NaCl, pH 7.40) and added to a 96-well plate containing final concentrations of 20 µM Aβ42, 5 µM ThT, and incubated at 37 °C for 24 h to generated Aβ42 fibrils. Amentoflavone (AMF) and
bilobetin (BIL) were kindly gifted from Dr. Sam Sik Kang at Seoul National University, Seoul, South Korea. Sequoiaflavone (SQF), sotetsuflavone (STF), and podocarpusflavone (PCF) were provided by Dr. Kiyotaka Koyama at Meiji Pharmaceutical University. To determine the ability of the biflavonoids on promoting disaggregation of Aβ42 fibrils, the test compounds at various concentrations were added to the preformed Aβ42 fibrils and continued incubating at 37 °C for 6 h. The ThT fluorescence was measured at 508 nm (excitation at 460 nm) on a Bio-Tek plate reader. The half maximum effective concentration (EC50) values were calculated using the GraphPad Prism 8 software (San Diego, CA, USA).

3.2. Docking

Structures for five biflavonoids—amentoflavone (AMF), bilobetin (BIL), podocarpusflavone (PCF), sequoiaflavone (SQF), and sotetsuflavone (STF)—were built in the Avogadro molecule editor and viewer [45] and parameterized using Gaussian09 (Wallingford, CT, USA) [46] at the Hartree-Fock/6-31G* level of theory. To identify potential inhibitor binding sites, molecular docking calculations were performed with AutoDock Vina (La Jolla, CA, USA) [47] via the PyRx interface. The parametrized structures were docked to a receptor model of a disease-relevant Aβ42 fibril obtained from the Protein Databank (PDB: 2NAO) [37]. To generate an initial MD structure, each biflavonoid was docked to the fibril structure using the entire fibril surface as the search space. Eight poses were generated per biflavonoid and ranked by docking score. For each biflavonoid, the most favorable pose in complex with the fibril receptor was used as the starting structure for MD. The fibril structure without a bound biflavonoid was also used to initiate an MD simulation for a control group. In an effort to compare docking scores to ThT assay EC50 values, a more exhaustive docking method was used. Each biflavonoid was docked using ten random seeds, and ten docking poses were generated per random seed, resulting in 100 docking poses for each biflavonoid. The generated poses were then clustered using a 2.0 Å cutoff, and the average docking score was computed for each cluster.

3.3. MD with Amber

The ff14SB force field [48] was applied to the protein. The tleap module of AmberTools (San Francisco, CA, USA) [49] was used to neutralize the system through the addition of Na+, Cu2+, and Cl− counter ions. The system was solvated using a truncated octahedral unit cell with TIP3P water molecules [50] and a 12.0 Å solvent buffer between the solute and edge of the unit cell. GAFF forcefield parameters [51] were generated for each biflavonoid using the antechamber module of AmberTools. Constant volume and pressure were maintained during all simulations. Minimization, heating, and equilibration for each system were performed in accordance with other published works [52,53] and unrestrained MD was run at 310.0 K to a completion time of 1.0 µs for each system. This was performed with a 2.0-fs time step saving energies, coordinates, and velocities every 50,000 steps. Each of the six simulations were propagated for 1.0 µs for an overall total of 6.0 µs.

3.4. MD Analysis

The cpptraj module [54] of Amber16 (San Francisco, CA, USA) was used to perform root mean square deviation (RMSD), hydrogen bonding, secondary structure calculations, and principal component analysis (PCA). RMSD was used to determine the amount to which each system varied from the starting coordinates. Hydrogen bonding calculations were used to determine specific hydrogen bonds that were important for biflavonoid-fibril interaction. Hydrogen bonds were defined as having a bonding angle of 135° and a distance of 3.0 Å from acceptor to donor heavy atom. To quantify the effect of biflavonoid influence on fibril structure, per residue secondary structure was measured over the course of each trajectory by assigning each residue a DSSP value for every frame. PCA was utilized to reduce the dimensionality of the MD simulations to gain insight into biologically relevant protein motions. PCA of the coordinate covariance matrix was performed to determine the dominant motions of the peptide backbone throughout the simulated trajectories. The
Normal Mode Wizard plug-in of Visual Molecular Dynamics (VMD) (Champaign, IL, USA) [55], was used to generate porcupine plots, providing a visual representation of each principal component. In order to analyze the solvation free energies of each residue for the individual systems, a per-residue free energy decomposition of each system was computed using the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) approach utilizing MMPBSA.py [56]. Per-residue free energy calculations were performed on all coordinates of the 1.0 µs simulations (60,000 frames) using the HCT Generalized Born solvation model [57]. Visualization of the completed trajectories was carried out using Visual Molecular Dynamics (VMD) [55] and UCSF Chimera (San Francisco, CA, USA) [58].

4. Conclusions

Aβ42 fibril aggregates are theorized to be toxic protein species that are pathologically linked to neurodegeneration and AD. This makes the development and discovery of aggregation inhibitors essential for AD treatment. The naturally occurring class of polyphenolic molecules known as biflavonoids exhibit activity that promotes the disaggregation of existing Aβ42 in vitro. Thioflavin T fluorescence assays confirm that biflavonoid compounds do exhibit these effects, and the biflavonoids differ in disaggregating activity based on structural positioning of functional groups. We utilized computational techniques to provide the first atomic details of the dynamic interactions that influence the inhibitory effects of these biflavonoids. Molecular docking calculations revealed that the biflavonoids preferentially bind to the N-terminal pocket of the Aβ42 fibril due to the large number of aromatic residues present in the pocket. Furthermore, MD simulations, per-residue free energy decomposition, PCA, secondary structure analysis, and hydrogen bond analysis led to several findings that help explain the inhibitory effects of the biflavonoids. Per-residue free energy decomposition calculations revealed that the biflavonoid molecules form stabilizing π–π interactions with the aromatic residues in the N-terminal pocket, which leads to a decrease in interactions between the Aβ42 peptides and promoting fibril destabilization. This was confirmed through secondary structure analysis which showed a larger decrease in β-sheet content over the course of the ligand-bound simulations relative to the ligand-free simulation. Additionally, PCA revealed that the biflavonoids cause the fibril structure to fold and twist, which decreases the hydrogen bonding potential within the peptide backbone of the fibril structure. Hydrogen bond analysis was further employed to elucidate the hydrogen bonding interactions between the biflavonoid and the fibril. It was determined that when hydroxyl groups are present at R2/R3, these R-groups hydrogen bond to the peptide backbone which disrupts the β-sheets of the fibril. These interactions ultimately lead to disruption of the fibril structure and suggest that hydroxyl groups at R2/R3 are key to promoting fibril deformation. Altogether, these results suggest that biflavonoids are initially bound to the Aβ42 fibril by the significant number of aromatic amino acids found in residues 4–14, forming favorable π–π interactions between the peptides and the biflavonoids. Once bound to this region of the fibril, the biflavonoids position themselves between the Aβ42 peptides and utilize the hydrogen bond donors/acceptors at the R2/R3 positions to specifically disrupt the backbone hydrogen bonding occurring between peptides in the native fibril. Our atomistic docking, simulations, and analysis support this mechanism of disaggregation for these bioflavonoids. The biflavonoid compounds presented here represent a class of molecules that can effectively act as aggregation inhibitors due to their ability to disrupt the fibril structure. Future studies will investigate biflavonoid modifications and derivatives to further examine the efficacy of these compounds as aggregation inhibitors.

Our study has several limitations. First, our experiments with the ThT assay were performed in a cell-free system; therefore, the effects of biflavonoids on disaggregation of Aβ42 may not be generalized to the in vitro and in vivo settings. Second, our study focused solely on the structure-activity relationship of biflavonoids in disaggregating Aβ42 fibrils and computational analysis of their potential interactions at the atomic levels utilizing the fibrillar structure of Aβ42 tetramer (PDB: 2NAO). Since amyloid plaques found
in patients with AD consist of multiple Aβ species (such as Aβ40 and Aβ42) and other proteins, it is possible that biflavonoids may have different effects on disaggregating these amyloid plaques in in vivo rodent models and/or human patients with AD. Third, our data clearly demonstrated that biflavonoids directly interact with Aβ42 fibrils, leading to disaggregation to less ordered Aβ42. However, the significance of biflavonoid-driven structural changes in Aβ42 fibrils regarding amyloid metabolism, clearance, deposition, and neurotoxicity in cell culture as well as in vivo models remains to be determined. To address these limitations, we are currently testing how biflavonoids, in particular amentoflavone, affect the cellular clearance of Aβ aggregates in the brain parenchymal cells and the cerebrovascular cells where the extracellular deposition of Aβ aggregates occur in the brain. In addition, we are performing an in vivo study to investigate the effects of amentoflavone on Aβ disaggregation and neurological outcome using the transgenic mouse model of Alzheimer’s disease.

Supplementary Materials: The following are available online at https://www.mdpi.com/1422-0067/22/6/2888/s1. Figure S1. Projection of the individual trajectories onto modes 1 and 2 (A), modes 1 and 3 (B), and modes 2 and 3 (C) for the five ligand-bound simulations and the ligand-free simulation showing the difference in motion between systems. Figure S2. Porcupine plots of the first dominant mode of motion (A and D), second dominant mode of motion (B,E), and third dominant mode of motion (C and F) for the concatenated trajectory of the five ligand-bound simulations and the ligand-free simulation. Figure S3. (A) Change in % β-sheet content over time for the MD trajectories averaged every 25 ns. Figure S4. Decrease in β-sheet content relative to starting β-sheet content at time points: 5 ns, 50 ns, and 500 ns. Figure S5. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with no ligand. Figure S6. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with amentoflavone. Figure S7. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with bilobetin. Figure S8. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with podocarpusflavone. Figure S9. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with sequoiaflavone. Figure S10. Protein backbone hydrogen bonding analysis derived from simulation of Aβ42 with sotetsuflavone. Table S1. ΔG_decomp, ΔG_vdw, ΔG_elec, ΔG_polar, and ΔG_nonpolar of all residues averaged across the five ligand-bound simulations. Table S2. Total number of backbone hydrogen bonds on the Aβ42 fibril and their associated prevalence during each 1.0-µs simulation performed.

Author Contributions: B.R.M.III and B.H.H. conceived the initial idea and supervised the study and overall preparation of the manuscript. P.K.W., S.P.P., D.S.M. and J.C.B. performed the computational analysis. P.K.W. and E.Y.C. carried out the ThT binding assay and data analysis. P.K.W., S.P.P., D.S.M., B.R.M.III and B.H.H. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: Computational resources were provided, in part, by the MERCURY supercomputer consortium under NSF Grants CHE-1229354 and CHE-1626238. This study was supported, in part, by ATSU Warner/Ferumatro Grant.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Rocca, W.A.; Petersen, R.C.; Knopman, D.S.; Hebert, L.E.; Evans, D.A.; Hall, K.S.; Gao, S.; Unverzagt, F.W.; Langa, K.M.; Larson, E.B.; et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimer’s Dement. 2011, 7, 80–93. [CrossRef]

2. Kandimalla, R.; Reddy, P.H. Therapeutics of Neurotransmitters in Alzheimer’s Disease. J. Alzheimer’s Dis. 2017, 57, 1049–1069. [CrossRef] [PubMed]

3. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10, 698–712. [CrossRef]
4. Ashraf, G.M.; Greig, N.H.; Khan, T.A.; Hassan, I.; Tabrez, S.; Shakil, S.; Sheikh, I.A.; Zaidi, S.K.; Akram, M.; Jabir, N.R.; et al. Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 2014, 13, 1280–1293. [CrossRef] [PubMed]

5. Guo, J.L.; Lee, V.M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014, 20, 130–138. [CrossRef] [PubMed]

6. Cohen, S.I.; Linse, S.; Luheishi, L.M.; Hellstrand, E.; White, D.A.; Rajah, L.; Otzen, D.E.; Vendruscolo, M.; Dobson, C.M.; Knowles, T.P. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA 2013, 110, 9758–9763. [CrossRef]

7. Lee, S.J.; Nam, E.; Lee, H.J.; Savelieff, M.G.; Lim, M.H. Towards an understanding of amyloid-beta oligomers: Characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 2017, 46, 310–323. [CrossRef]

8. Dasilva, K.A.; Shaw, J.E.; McLaurin, J. Amyloid-beta fibrillation: Structural insight and therapeutic intervention. Exp. Neurol. 2010, 223, 311–321. [CrossRef]

9. Nieuwpoort, B.; De Vos, A.; Geng, M.Y. Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer’s disease. Acta Pharm. Sin. 2011, 32, 545–551. [CrossRef]

10. Soto, C.; Sigurdsson, E.M.; Morelli, L.; Kumar, R.A.; Castano, E.M.; Frangione, B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer’s therapy. Nat. Med. 1998, 4, 822–826. [CrossRef]

11. Goyal, D.; Shuaib, S.; Mann, S.; Goyal, B. Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-beta (Abeta) Aggregation: Potential Therapeutics for Alzheimer’s Disease. ACS Comb. Sci. 2017, 19, 55–80. [CrossRef]

12. Kim, H.; Park, B.S.; Lee, K.G.; Choi, C.Y.; Jang, S.S.; Kim, Y.H.; Lee, S.E. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J. Agric. Food Chem. 2005, 53, 8537–8541. [CrossRef] [PubMed]

13. Kang, S.S.; Lee, J.Y.; Choi, Y.K.; Song, S.S.; Kim, J.S.; Jeon, S.J.; Han, Y.N.; Son, K.H.; Han, B.H. Neuroprotective effects of naturally occurring biflavonoids. Biomo. Med. Chem. Lett. 2005, 15, 3588–3591. [CrossRef] [PubMed]

14. Churches, Q.L.; Caine, J.; Cavanagh, K.; Waddington, C.E.; Meyer, A.G.; Varghese, J.N.; Streltsov, V.; Duggan, P.J. Naturally occurring polyphenolic inhibitors of amyloid beta aggregation. Biomo. Med. Chem. Lett. 2014, 24, 3108–3112. [CrossRef] [PubMed]

15. Hirohata, M.; Hasegawa, K.; Tsutsumi-Yasuhara, S.; Ohhashi, Y.; Ookushi, T.; Ono, K.; Yamada, M.; Naiki, H. The anti-amyloidogenic effect is exerted against Alzheimer’s beta-amylol fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry 2007, 46, 1888–1899. [CrossRef] [PubMed]

16. Thapa, A.; Woo, E.R.; Chi, E.Y.; Sharar, M.G.; Jin, H.G.; Shin, S.Y.; Park, I.S. Biflavonoids are superior to monoflavonoids in inhibiting amyloid-beta toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures. Biochemistry 2011, 50, 2445–2455. [CrossRef]

17. Merlini, G.; Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 2003, 349, 583–596. [CrossRef]

18. Meis, G.; Yang, X.; Hellstrand, E.; Frohm, B.; Kirkegaard, J.B.; Cohen, S.I.; Dobson, C.M.; Linse, S.; Knowles, T.P. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Abeta40 and Abeta42 peptides. Proc. Natl. Acad. Sci. USA 2014, 111, 9384–9389. [CrossRef] [PubMed]

19. Xiao, Y.; Ma, B.; McElheny, D.; Parthasarathy, S.; Long, F.; Hoshi, M.; Nussinov, R.; Ishii, Y. Abeta(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat. Struct. Mol. Biol. 2015, 22, 499–505. [CrossRef]

20. Kuperstein, I.; Broersen, K.; Benilova, I.; Rozenski, J.; Jonckheere, W.; Debulpaep, M.; Vandersteen, A.; Segers-Nolten, I.; Van Der Werf, K.; Subramaniam, V.; et al. Neurotoxicity of Alzheimer’s disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010, 29, 3408–3420. [CrossRef]

21. Gremer, L.; Scholzel, D.; Schenk, C.; Reinartz, E.; Labahn, J.; Ravelli, R.B.G.; Tusche, M.; Lopez-Iglesias, C.; Hoyer, W.; Heise, H.; et al. Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy. Science 2017, 358, 116–119. [CrossRef] [PubMed]

22. Petkova, A.T.; Ishii, Y.; Balbach, J.J.; Antzutkin, O.N.; Leapman, R.D.; Delaglio, F.; Tycko, R. A structural model for Alzheimer’s beta-amylol fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA 2002, 99, 16742–16747. [CrossRef] [PubMed]

23. Ono, K.; Li, L.; Takamura, Y.; Yoshiike, Y.; Zhu, L.; Han, F.; Mao, X.; Ikeda, T.; Takasaki, J.; Nishijo, H.; et al. Phenolic compounds prevent amyloid beta-protein oligomerization and synaptic dysfunction by site-specific binding. J. Biol. Chem. 2012, 287, 14631–14643. [CrossRef]

24. Lemkul, J.A.; Bevan, D.R. The role of molecular simulations in the development of inhibitors of amyloid beta-peptide aggregation for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2012, 3, 845–856. [CrossRef]

25. Nasica-Labouze, J.; Nguyen, P.H.; Sterpone, F.; Berthoumieu, O.; Buchete, N.V.; Cote, S.; De Simone, A.; Doig, A.J.; Faller, P.; Garcia, A.; et al. Amyloid beta Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies. Chem. Rev. 2015, 115, 3518–3563. [CrossRef]

26. Biancalana, M.; Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta 2010, 1804, 1405–1412. [CrossRef]

27. Colvin, M.T.; Silvers, R.; Ni, Q.Z.; Can, T.V.; Sergeyev, I.; Rosay, M.; Donovan, K.J.; Michael, B.; Wall, J.; Linse, S.; et al. Atomic Resolution Structure of Monomorphic Abeta42 Amyloid Fibrils. J. Am. Chem. Soc. 2016, 138, 9663–9674. [CrossRef] [PubMed]
28. Shin, D.H.; Bae, Y.C.; Kim-Han, J.S.; Lee, J.H.; Choi, I.Y.; Son, K.H.; Kang, S.S.; Kim, W.K.; Han, B.H. Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms. *J. Neurochem.* 2006, 96, 561–572. [CrossRef]

29. Tian, Z.; Tang, C.; Wang, Z. Neuroprotective effect of ginkgetin in experimental cerebral ischemia/reperfusion via apoptosis inhibition and PI3K/Akt/mTOR signaling pathway activation. *J. Cell Biochem.* 2019, 120, 18487–18495. [CrossRef]

30. Cao, B.; Zeng, M.; Zhang, Q.; Zhang, B.; Cao, Y.; Wu, Y.; Feng, W.; Zheng, X. Amentoflavone Ameliorates Memory Deficits and Abnormal Autophagy in Abeta25-35-Induced Mice by mTOR Signaling. *Neurochem. Res.* 2021. [CrossRef]

31. Thapa, A.; Chi, E.Y. Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer’s Disease. *Adv. Exp. Med. Biol.* 2015, 863, 55–77. [CrossRef] [PubMed]

32. Uddin, M.S.; Kabir, M.T.; Tewari, D.; Mathew, B.; Aleya, L. Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer’s disease. *Sci. Total Environ.* 2020, 700, 134836. [CrossRef] [PubMed]

33. Zhao, N.; Sun, C.; Zheng, M.; Liu, S.; Shi, R. Amentoflavone suppresses amyloid beta1-42 neurotoxicity in Alzheimer’s disease through the inhibition of pyroptosis. *Life Sci.* 2019, 239, 117043. [CrossRef] [PubMed]

34. Cao, Q.; Qin, L.; Huang, F.; Wang, X.; Yang, L.; Shi, H.; Wu, H.; Zhang, B.; Chen, Z.; Wu, X. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through PI3K/Akt and ERK signaling pathways. *Toxicol. Appl. Pharm. 2017, 319, 80–90. [CrossRef] [PubMed]

35. Sirimangkalakitti, N.; Juliawaty, I.D.; Hakim, E.H.; Waliana, I.; Saito, N.; Koyama, K.; Kinoshita, K. Naturally occurring biflavonoids with amyloid beta aggregation inhibitory activity for development of anti-Alzheimer agents. *Bioorg. Med. Chem. Lett.* 2019, 29, 1994–1997. [CrossRef]

36. Sun, L.; Sharma, A.K.; Han, B.H.; Mirica, L.M. Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble Abeta42 Oligomers. *ACS Chem. Neurosci.* 2020, 11, 2741–2752. [CrossRef]

37. Walti, M.A.; Ravotti, F.; Arati, H.; Glabe, C.G.; Wall, J.S.; Bockmann, A.; Guntert, P.; Meier, B.H.; Riek, R. Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril. *Proc. Natl. Acad. Sci. USA 2016, 113, E4976–E4984. [CrossRef]

38. Choi, E.Y.; Kang, S.S.; Lee, S.K.; Han, B.H. Polyphenolic Biflavonoids Inhibit Amyloid-Beta Fibrillation and Disaggregate PreforMed. *Amyloid-Beta Fibrils. Biomol. Ther. (Seoul) 2020, 28, 145–151. [CrossRef] [PubMed]

39. Wang, Q.; Yu, X.; Patel, K.; Hu, R.; Chuang, S.; Zhang, G.; Zheng, J. Tanshinones inhibit amyloid aggregation by amyloid-beta peptide, disaggregate amyloid fibrils, and protect cultured cells. *ACS Chem. Neurosci.* 2013, 4, 1004–1015. [CrossRef]

40. Desdouits, N.; Nilges, M.; Blondel, A. Principal Component Analysis reveals correlation of cavities evolution and functional motions in proteins. *J. Mol. Graph. Model* 2015, 55, 13–24. [CrossRef]

41. Pierdominici-Sottile, G.; Palma, J. New insights into the meaning and usefulness of principal component analysis of concatenated trajectories. *J. Comput. Chem.* 2015, 36, 424–432. [CrossRef]

42. David, C.C.; Jacobs, D.J. Principal component analysis: A method for determining the essential dynamics of proteins. *Methods Mol. Biol.* 2014, 1084, 193–226. [CrossRef]

43. Ryan, T.M.; Friedhuber, A.; Lind, M.; Howlett, G.J.; Masters, C.; Roberts, B.R. Small amyphathic molecules modulate secondary structure and amyloid fibril-forming kinetics of Alzheimer disease peptide Abeta(1-42). *J. Biol. Chem.* 2012, 287, 16947–16954. [CrossRef] [PubMed]

44. McKoy, A.F.; Chen, J.; Schupbach, T.; Hecht, M.H. A novel inhibitor of amyloid beta (Abeta) peptide aggregation: From high throughput screening to efficacy in an animal model of Alzheimer disease. *J. Biol. Chem.* 2012, 287, 38992–39000. [CrossRef] [PubMed]

45. Hanwell, M.D.; Curtis, D.E.; Lonie, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. *J. Cheminform.* 2012, 4, 17. [CrossRef] [PubMed]

46. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. Gaussian 09, Revision A. 02, Gaussian, Inc., Wallingford CT, 2016 Search PubMed;(b) J. Chaia and M. Head-Gordon. *Phys. Chem. Chem. Phys.* 2010, 12, 6615–6620.

47. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 2009, 30, 2785–2791. [CrossRef]

48. Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. *J. Chem. Theory Comput.* 2015, 11, 3696–3713. [CrossRef]

49. Case, D.A.; Cerutti, D.; Cheatham, T.E., III; Darden, T.A.; Duke, R.E.; Giese, T.J.; Gohlke, H.; Goetz, A.W.; Homeyer, N.; Izadi, S.; et al. AMBER 2016; University of California: San Francisco, CA, USA, 2016.

50. Jorgensen, W.L. Quantum and statistical mechanical studies of liquids. 25. Solvation and conformation of methanol in water. *J. Am. Chem. Soc.* 1983, 105, 1407–1413. [CrossRef]

51. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. *J. Comput. Chem.* 2004, 25, 1157–1174. [CrossRef]

52. Miller, B.R., 3rd; Beese, L.S.; Parish, C.A.; Wu, E.Y. The Closing Mechanism of DNA Polymerase I at Atomic Resolution. *Structure 2015, 23, 1609–1620. [CrossRef]

53. Miller, B.R., 3rd; Parish, C.A.; Wu, E.Y. Molecular dynamics study of the opening mechanism for DNA polymerase I. *PLoS Comput. Biol.* 2014, 10, e1003961. [CrossRef] [PubMed]
54. Roe, D.R.; Cheatham, T.E., 3rd. PTRAJ and CPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J. Chem. Theory Comput. 2013, 9, 3084–3095. [CrossRef] [PubMed]

55. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33–38. [CrossRef]

56. Miller, B.R., 3rd; McGee, T.D., Jr.; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J. Chem. Theory Comput. 2012, 8, 3314–3321. [CrossRef] [PubMed]

57. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [CrossRef] [PubMed]

58. Hawkins, G.D.; Cramer, C.J.; Truhlar, D.G. Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium. J. Phys. Chem. 1996, 100, 19824–19839. [CrossRef]